Skip to main content
Fig. 4 | Genome Biology

Fig. 4

From: The evolution of alternative splicing in glioblastoma under therapy

Fig. 4

a An overview of the neoantigen discovery pipeline. b The numbers of primary-tumor enriched, recurrent-tumor-enriched, and shared putative neojunction-derived neoantigens. c The frequencies of neojunction-derived neoantigens in primary vs. recurrent GBM. d The HLA-I predicted binding affinities of neojunction-derived neoantigens in primary vs. recurrent GBM

Back to article page